Does Keytruda Have a Generic Version?
Keytruda (pembrolizumab) has no FDA-approved generic equivalent. As a biologic monoclonal antibody, it cannot have traditional small-molecule generics. Instead, biosimilars—highly similar versions from other manufacturers—are the closest alternative, but none are approved or available in the US market as of 2024.[1]
How Do Biosimilars Compare to Keytruda in Effectiveness?
Approved Keytruda biosimilars, like those in Europe (e.g., Keytruda biosimilar by Samsung Bioepis, authorized by EMA in 2024), show clinical equivalence to the reference product in trials. They match Keytruda's efficacy, safety, and immunogenicity in non-small cell lung cancer and other indications, with progression-free survival and overall survival rates within regulatory standards (e.g., no more than 1.25-fold difference in risk ratios).[2][3]
US approval awaits FDA review; the first applications are under evaluation, with potential launches post-patent expiry around 2028-2031, depending on litigation.[1]
What Do Real-World Studies and Trials Show?
Head-to-head trials for biosimilars demonstrate:
- Equivalent objective response rates (around 40-50% in first-line NSCLC with pemetrexed/platinum).
- Comparable overall survival (median 22-26 months).
- Similar adverse event profiles, including immune-related issues like pneumonitis (10-15%).
No US data exists yet due to lack of availability, but global evidence from over 500-patient trials supports interchangeability.[2]
When Could US Biosimilars Launch and at What Cost Savings?
Patent challenges target Keytruda's composition-of-matter patent (expires 2028) and method-of-use extensions (up to 2036). Merck has settled some suits, allowing limited entry by 2028; others face trials.[1]
Biosimilars typically cost 20-30% less initially, dropping to 70-80% with competition—potentially saving $10B+ annually in the US, where Keytruda generated $25B in 2023 sales.[1][4]
| Aspect | Keytruda (Originator) | Biosimilars (Expected) |
|--------|-----------------------|-------------------------|
| Efficacy | Reference standard | Clinically equivalent per trials |
| Price | $11K/month | $8-9K/month initially |
| Availability | US now; global | EU now; US ~2028+ |
What Risks or Differences Do Patients Face?
Switching to biosimilars shows no loss in effectiveness in post-approval studies, but minor manufacturing differences may affect rare immune responses. FDA requires switching studies for interchangeability labels. Oncologists report seamless transitions in Europe.[3]
[1]: DrugPatentWatch.com - Keytruda Patents
[2]: EMA Assessment Report, Samsung Bioepis Pembrolizumab (2024)
[3]: FDA Biosimilars Guidance (2023)
[4]: Merck Q4 Earnings (2023)